Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (899)	3/9/1999 1:13:00 AM
From: John Starks	Read Replies (1) \| Respond to of 3202

A very provocative post doc :) . It would seem that going downstream of gene expression to screen for drugs would allow you to filter through all the noise of the genome. These combinatorial library approaches to drug development are intriguing and certainly powerful but they will not, IMO, replace genomics based discovery. The peptide library will be screened functionally against known protein targets. This type of screen will not identify novel disease causing/associated genes, which is the promise of genomics. The peptide approach is complimentary as of now to gene discovery efforts. Thanks for the interesting post. I will have to watch out for Axcell publications in the near future.